Cancer

December 14, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Niclosamide and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 14/December/2018, 11.59 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Niclosamide and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 14/December/2018, 11.59 pm https://genomediscovery.org/wp-content/uploads/2018/12/Nicolasamide-functions-as-an-antitumor-metastasis-by-increasing-the-expression-of-APAF1-and-RB1.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/Nicolasamide-functions-as-an-antitumor-metastasis-by-increasing-the-expression-of-APAF1-and-RB1.jpg2_.jpg December 14, 2018 December 14, 2018

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

December 13, 2018

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 13/December/2018, `11.27 pm

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 13/December/2018, `11.27 pm https://genomediscovery.org/wp-content/uploads/2018/12/P-5.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/P-5.jpg December 13, 2018 December 13, 2018

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors…

December 13, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing SAHA (Suberoylanilide Hydroxamic Acid) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 13/December/2018, `11.01 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing SAHA (Suberoylanilide Hydroxamic Acid) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 13/December/2018, `11.01 pm https://genomediscovery.org/wp-content/uploads/2018/12/SAHA-functions-as-an-antitumor.metastasis-agent-by-increasing-the-expression-of-tumor.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/SAHA-functions-as-an-antitumor.metastasis-agent-by-increasing-the-expression-of-tumor.jpg December 13, 2018 December 13, 2018

December 12, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/December/2018, `10.47 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/December/2018, `10.47 am https://genomediscovery.org/wp-content/uploads/2018/12/MiR129-and-the-probiotic-Lactobacillus-rhamnosus-attenuate-tumor-progression-through-induction-of-TPM1-and-CCM3.jpg3_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/MiR129-and-the-probiotic-Lactobacillus-rhamnosus-attenuate-tumor-progression-through-induction-of-TPM1-and-CCM3.jpg3_.jpg December 12, 2018 December 12, 2018

December 11, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing lncRNA Hand2-AS1 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as KIBRA, p57Kip2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 9/December/2018, `11.36pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing lncRNA Hand2-AS1 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as KIBRA, p57Kip2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 9/December/2018, `11.36pm https://genomediscovery.org/wp-content/uploads/2018/12/LncRNA-Hand2AS1-and-the-probiotic-Lactobacillus-increase-the-expresison-of-p57Kip2-and-KIBRA-and-attenuate-tumor-progression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/LncRNA-Hand2AS1-and-the-probiotic-Lactobacillus-increase-the-expresison-of-p57Kip2-and-KIBRA-and-attenuate-tumor-progression.jpg December 11, 2018 December 11, 2018

December 11, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Pimozide, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, CADM1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 11/December/2018, 11.29 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Pimozide, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, CADM1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 11/December/2018, 11.29 pm https://genomediscovery.org/wp-content/uploads/2018/12/Neuroleptic-drug-Pimozide-and-the-probiotic-Lactobacillus-increase-the-expression-of-PDCD4-and-CADM1-and-attenuate-tumor-progression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/Neuroleptic-drug-Pimozide-and-the-probiotic-Lactobacillus-increase-the-expression-of-PDCD4-and-CADM1-and-attenuate-tumor-progression.jpg December 11, 2018 December 11, 2018

Popular Post